NO890833L - Fremstilling av kallikrein. - Google Patents

Fremstilling av kallikrein.

Info

Publication number
NO890833L
NO890833L NO89890833A NO890833A NO890833L NO 890833 L NO890833 L NO 890833L NO 89890833 A NO89890833 A NO 89890833A NO 890833 A NO890833 A NO 890833A NO 890833 L NO890833 L NO 890833L
Authority
NO
Norway
Prior art keywords
callique
preparation
kallikrein
kallikreins
procaryotic
Prior art date
Application number
NO89890833A
Other languages
English (en)
Norwegian (no)
Other versions
NO890833D0 (no
Inventor
Fu-Kuen Lin
Hsieng Sen Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO890833D0 publication Critical patent/NO890833D0/no
Publication of NO890833L publication Critical patent/NO890833L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
NO89890833A 1987-06-30 1989-02-27 Fremstilling av kallikrein. NO890833L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6859487A 1987-06-30 1987-06-30
US21025688A 1988-06-27 1988-06-27
PCT/US1988/002214 WO1989000192A1 (en) 1987-06-30 1988-06-29 Production of kallikrein

Publications (2)

Publication Number Publication Date
NO890833D0 NO890833D0 (no) 1989-02-27
NO890833L true NO890833L (no) 1989-04-27

Family

ID=26749136

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89890833A NO890833L (no) 1987-06-30 1989-02-27 Fremstilling av kallikrein.

Country Status (14)

Country Link
EP (1) EP0297913B1 (ja)
JP (1) JPH01503679A (ja)
KR (1) KR890701731A (ja)
AT (1) ATE118547T1 (ja)
AU (1) AU627427B2 (ja)
DE (1) DE3853023T2 (ja)
DK (1) DK91389A (ja)
ES (1) ES2068201T3 (ja)
FI (1) FI890889A (ja)
GR (1) GR3015881T3 (ja)
NO (1) NO890833L (ja)
NZ (1) NZ225230A (ja)
PT (1) PT87887B (ja)
WO (1) WO1989000192A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4036392A1 (de) * 1990-11-15 1992-05-21 Behr Gmbh & Co Latentwaermespeicher
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0804593A1 (en) * 1994-05-10 1997-11-05 Mayo Foundation For Medical Education And Research Recombinant hk2 polypeptide
US5955306A (en) * 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US5840871A (en) * 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6376182B1 (en) 1997-05-14 2002-04-23 Medical University Of South Carolina Methods and compositions for correlating tissue kallikrein gene promoter polymorphisms with treatment of essential hypertension
US5948616A (en) * 1997-05-14 1999-09-07 Musc Foundation For Research Development Methods and compositions of correlating tissue kallikrein gene promoter polymorphisms with essential hypertension
WO1998059073A1 (en) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
CN101058800B (zh) 2002-07-09 2013-03-13 巴克斯特国际有限公司 用于细胞培养的无动物蛋白质培养基
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
WO2009039704A1 (fr) * 2007-09-27 2009-04-02 Shanghai Wanxing Biopharmaceuticals, Co., Ltd. Procédé de fabrication de kallikréine 1 humaine
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
US11857608B2 (en) 2017-03-09 2024-01-02 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905870A (en) * 1972-11-03 1975-09-16 Bayer Ag Purification of kallikrein
DE3103257A1 (de) * 1981-01-31 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung des hochreinen enzyms kallikrein aus schweinepankreas-extrakten
JPS5838151B2 (ja) * 1981-07-03 1983-08-20 衛 杉浦 カリクレインの精製法
JPS596883A (ja) * 1982-06-30 1984-01-13 Nippon Chem Res Kk 人尿カリクレインの濃縮精製法
JPS59102392A (ja) * 1982-12-02 1984-06-13 Nippon Chem Res Kk 熱安定性を有するヒト尿キニノゲナーゼ水溶液の製造法
JPS6092220A (ja) * 1983-10-26 1985-05-23 Ss Pharmaceut Co Ltd カリクレインの精製法
JPS6121086A (ja) * 1984-07-10 1986-01-29 Amano Pharmaceut Co Ltd カリクレインおよびエラスタ−ゼの取得方法
EP0234095A3 (en) * 1985-10-24 1988-06-15 Biotechnology Research Partners, Ltd. Blood tests diagnostic for hypertension
JPS62126980A (ja) * 1985-11-26 1987-06-09 Shigetada Nakanishi Ｄｎａ断片

Also Published As

Publication number Publication date
ATE118547T1 (de) 1995-03-15
FI890889A0 (fi) 1989-02-24
WO1989000192A1 (en) 1989-01-12
KR890701731A (ko) 1989-12-21
GR3015881T3 (en) 1995-07-31
PT87887B (pt) 1994-05-31
EP0297913A2 (en) 1989-01-04
FI890889A (fi) 1989-02-24
DE3853023D1 (de) 1995-03-23
ES2068201T3 (es) 1995-04-16
EP0297913B1 (en) 1995-02-15
NZ225230A (en) 1991-06-25
AU2075588A (en) 1989-01-30
AU627427B2 (en) 1992-08-27
PT87887A (pt) 1989-05-31
DK91389D0 (da) 1989-02-27
NO890833D0 (no) 1989-02-27
DE3853023T2 (de) 1995-06-08
DK91389A (da) 1989-05-01
JPH01503679A (ja) 1989-12-14
EP0297913A3 (en) 1990-03-07

Similar Documents

Publication Publication Date Title
NO890833L (no) Fremstilling av kallikrein.
NO871785L (no) Fremgangsmaate for fremstilling av et proteinprodukt samt vektorsystem for fremgangsmaatens utfoerelse.
FI844597L (fi) Foerfarande foer framstaellning av en synnerligen ren hyaluronsyra.
ATE248925T1 (de) Verfahren zur herstellung von proteinen oder proteinhaltigen genprodukten
DE69033032D1 (de) Integriertes zellkultur-proteinreinigungssystem zur automatisierten herstellung und reinigung von zellkulturprodukten
AU6733487A (en) Mammalian interleukin-4
IL88223A0 (en) Polypeptides,process,nucleotide sequences,expression vectors and host organisms for their production and pharmaceutical compositions comprising them
PH25120A (en) Replicable expression vehicle and process of preparation thereof
ATE124086T1 (de) Herstellung von proteinen.
NO891716D0 (no) Ekspresjon av humant serumalbumin i metylotrofe gjaersorter
DE3851035D1 (de) Interleukin-7.
ATE2442T1 (de) Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung.
FR2607517B2 (fr) Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu
DE69432856D1 (de) Zufuhr von genprodukten mittels mesangium-zellen